Skip to main content
NCBI home page
Iranian Journal of Basic Medical Sciences logoLink to Iranian Journal of Basic Medical Sciences
. 2020 Mar;23(3):329–336. doi: 10.22038/IJBMS.2019.39291.9320

Inhibition of miR-22 enhanced the efficacy of icotinib plus pemetrexed in a rat model of non-small cell lung cancer

Jing Zhang 1, Zhi-Qiang Xue 1, Bin Wang 1, Jia-Xin Wen 1, Yun-Xi Wang 1,*
PMCID: PMC7229502  PMID: 32440319

Abstract

Objective(s):

To investigate the role of miR-22 in the efficacy of combined icotinib (BPI-2009H) and pemetrexed (LY-231514) on tumor growth and apoptosis in rats with non-small cell lung cancer (NSCLC).

Materials and Methods:

Rats were injected with HCC827 cells, which were transfected with anti-miR-22, followed by the treatment of BPI-2009H and/or LY-231514. MTT assay was used to detect the inhibition rate of HCC827 cells. qRT-PCR was performed to examine miR-22 expression in HCC827 cells and lung tumor tissues. Moreover, immunohistochemistry and Western blotting were performed to detect the related-molecule expressions, while TUNEL staining was used to observe cell apoptosis of lung tumor tissues.

Results:

MiR-22 expression was decreased in HCC827 cells after the treatment of BPI-2009H or LY-231514 in a dose-dependent manner. Both BPI-2009H and LY-231514 increased the inhibition rate of HCC827 cells, which was enhanced by anti-miR-22 with decreased IC50 values. Furthermore, the decreased expression of miR-22 was found after the treatment of BPI-2009H or/and LY-231514 in lung tumor tissues. In addition, the expressions of PCNA, Ki67, and Bcl-2 were reduced, but Bax and Caspase-3 were increased in treated rats, typically in those rats treated with the combination of anti-miR-22, BPI-2009H, and LY-231514.

Conclusion:

Inhibition of miR-22 could enhance the efficacy of icotinib combined with pemetrexed in rats with NSCLC, providing a new perspective for NSCLC therapy.

Key Words: Carcinoma, Human, Icotinib, MIRN22 microRNA, Non-Small-Cell Lung, Pemetrexed

Introduction

Lung cancer has become one of the most common malignant tumors around the world, among which the number of non-small cell lung cancer (NSCLC) cases accounts for about 80%~85% (1), with over 50% of these patients in the late/advanced stage at the time of diagnosis (2). Chemotherapy has been the main therapy for advanced NSCLC so far, but the prognosis is poor, as recorded, the median overall survival time was shorter than 12 months, and the 5-year survival rate was less than 1% (3). Recent research shows, molecule-targeted medicine with epidermal growth factor receptor (EGFR) as a therapeutic target may effectively improve responses to treatment and prolong progression-free survival (PFS), playing an essential role in the treatment of NSCLC (1, 4, 5), which mainly consists of two types: small-molecule tyrosine kinase inhibitors (TKIs) like afatinib, gefitinib, icotinib, as well as monoclonal antibodies (6). Given the different antitumor effects of mechanism, the combination therapy of EGFR-TKI and chemotherapy has become the hotspot, which could reduce the dose of chemotherapy drugs with decreased overlapping toxicities, and effectively improve the antitumor ability, to be widely used in the clinical treatment of cancers (7, 8).

Pemetrexed is a multi-targeting, anti-metabolite, and anti-folate chemotherapy drug by inhibiting thymidylate synthase (TS), dihydrofolate reductase (DHFR), and several other folate-dependent enzymes, which were implicated in the metabolism and synthesis of DNA precursors, and thereby preventing the formation of DNA and leading to the potent antitumor ability(9, 10). It is of significant advantage to be widely used to treat patients with NSCLC owing to its clinical curative effect as well as low toxic and side effects (11, 12). On the other hand, icotinib, as an effective and specific EGFR-TKI, especially for EGFR-mutant NSCLC, is fat-soluble and safe, and it can easily cross the blood-brain barrier or cell membrane, thus having positive antitumor effects in the clinical treatment of NSCLC (13). Of note, the pemetrexed-based chemotherapy plus icotinib therapy strategy is a promising choice for the treatment of advanced lung cancer (14).

MicroRNAs (miRNAs) are a class of small single-stranded non-coding RNAs with the length of 19-25 bp (15). An increasing number of studies have shown that miRNAs may exert oncogenes or tumor suppressor functions in different types of cancers, which are widely accepted as a diagnostic marker for the evaluation of tumor prognosis and the prediction of treatment efficacy (16, 17). MiR-22, an evolutionarily-conserved gene located in chromosome 17p13, could inhibit lung cancer cell EMT and invasion, thus suppressing lung cancer cell progression (18, 19). It is worthy of mentioning that miR-22 clinically served as a sensitizer in several cancer treatments (20), with the function of increasing chemosensitivity to different anticarcinogens. For example, miR-22 could re-sensitize the paclitaxel-resistant colon cancer cells to paclitaxel (21). Besides, both increased and decreased miR-22 enhanced the fulvestrant sensitivity of the fulvestrant-resistant breast cancer cells (22). Of note, there was a study stating that miR-22 overexpression was correlated with the poor efficacy of pemetrexed therapy in NSCLC patients (23). Furthermore, icotinib was also found capable of suppressing the Akt signaling pathway activation in human NSCLC cells (24), which was associated with miR-22 (25), hypothesizing that miR-22 may affect the icotinib efficacy in NSCLC. However, few studies have investigated whether miR-22 can influence the efficacy of icotinib combined with pemetrexed in the treatment of NSCLC. Therefore, the current research established a rat subcutaneous NSCLC model, injected pLVTHM-anti-miR-22 into the NSCLC rats, with the objective of exploring the inhibition role of miR-22 in the efficacy of BPI-2009H plus LY-231514 on tumor growth and apoptosis in rats with NSCLC.

Materials and Methods

Ethics statement

The animal experiment was approved by our Experimental Animal Ethics Committee of The First Medical Center of Chinese PLA General Hospital, and all procedures were strictly in accordance with relevant provisions of the experimental animal care and use created by the International Association for the Study Pain (26).

Subjects of study

Human NSCLC cell lines with an EGFR mutation of HCC827 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). A total of 100 nude male rats were purchased from the Beijing WeitongLihua Experimental Animal Technical Co. Ltd (Beijing, China), and housed in a sterile laminar flow chamber. The rats were fed at normal circadian rhythms, and they could take food and water ad libitum in a clean grade animal room at 22~25 t .

3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay

The effects of Icotinib (BPI-2009H) and Pemetrexed (LY-231514) on the inhibition rate of HCC827 cells were measured using the MTT assay. In brief, Cells (1 × 104) were seeded in 96-well plates followed by adding BPI-2009H (0.01, 0.1, 1, 10, and 100 μmol/l) or LY-231514 (0.01, 0.1, 1, 10, and 100 μg/ml) and MTT solution (5 mg/ml) for incubation at 37 °C for 4 hr. Then, the cells were lysed in 200 μl DMSO, and OD570 was measured with a microplate reader.

Establishment of the NSCLC rat models and grouping

HCC827 cells were digested with 0.25% trypsin and then diluted into a single cell suspension with fresh DMEM medium, which was then centrifuged, washed twice with ice-cold normal saline, and brought to a concentration of 2 × 107 cells/ml. Cell suspension (4 ×1012 cells) was inoculated into the subcutis of the back of nude rats using a 1-ml syringe. Animals were then housed in a sterile laminar flow chamber, and changes in tumor growth were observed. After tumors had grown to 1 cm (within 1 week) in diameter, the rats were divided into groups for later experiments. As shown in Table 1, Rats were randomly classified into 10 groups (10 rats per group). Icotinib (BPI-2009H) and Pemetrexed (LY-231514) were purchased from AMQUAR. Lentiviral vector pLVTHM-anti-miR-22 was provided by Hanheng Biotechnology Co., Ltd (Shanghai, China). From the 2nd week, the tumor size of each rat was measured once a week to calculate the volume of tumors (27), and the weight of rats was recorded. After 8 weeks of intervention treatment, rats were anesthetized, and their limbs were fixed to perform normal anatomy. The lung tumor tissue of rats was obtained, half of which was soaked with formalin to make paraffin-embedded tissue blocks, and the other half was preserved in a refrigerator at -80 °C for subsequent experiments.

Table 1.

Intervention treatments of all groups after the successful establishment of subcutaneous tumor inoculation

Group The 2nd week The 3rd week
Control Injection (IT) of normal saline Oral and injection (IP) of normal saline, 5 weeks
BPI-2009H Injection (IT) of normal saline BPI-2009H (oral 60 mg/kg/day), 5 weeks
LY-231514 Injection (IT) of normal saline Injection (IP) of LY-231514 (100 mg/kg/day), 5 weeks
Vector +BPI-2009H Injection (IT) of Vector (1nM) BPI-2009H (oral 60 mg/kg/day), 5 weeks
Vector +LY-231514 Injection (IT) of Vector (1nM) Injection (IP) of LY-231514 (100 mg/kg/day), 5 weeks
anti-miR-22 +BPI-2009H Injection (IT) of pLVTHM-anti-miR-22 (1nM) BPI-2009H (oral 60 mg/kg/day), 5 weeks
anti-miR-22 +LY-231514 Injection (IT) of pLVTHM-anti-miR-22 (1nM) Injection (IP) of LY-231514 (100 mg/kg/day), 5 weeks
BPI-2009H + LY-231514 Injection (IT) of normal saline BPI-2009H (oral 60 mg/kg/day) and injection (IP) of LY-231514 (100 mg/kg/day), 5 weeks
Vector + BPI-2009H + LY-231514 Injection (IT) of Vector (1nM) BPI-2009H (oral 60 mg/kg/day) and injection (IP) of LY-231514 (100 mg/kg/day), 5 weeks
anti-miR-22 + BPI-2009H + LY-231514 Injection (IT) of pLVTHM-anti-miR-22 (1nM) BPI-2009H (oral 60 mg/kg/day) and injection (IP) of LY-231514 (100 mg/kg/day), 5 weeks
Open in a new tab

IT: intratumoral; IP: intraperitoneal

qRT-PCR

The total RNA was extracted according to the instruction of Trizol (Invitrogen, USA), and the purity and concentration were measured by a NanoDrop2000 spectrophotometer (Thermo Scientific, Willmington, DE, USA). cDNA was synthesized using a stem-loop specific primer for miR-22 and then subjected to qRT-PCR using 2 μl of a 1:5 dilution of the reverse-transcribed cDNA and SYBR green in an ABI Fast Q-PCR machine (Applied Biosystems, Foster City, CA, USA). The cycling conditions were as follows: 50 °C for 2 min, 95 °C for 5 min, and 40 cycles of 95 °C for 15 sec followed by 60 °C for 1 min. Based on the gene sequences published in the Genbank database, the primers were designed with the software Primer 5.0 and synthesized by Shanghai Sangon Biotechnology Co. Ltd (Table 2). U6 was used as the internal reference gene and 2-Δ Δ Ct was applied to present the relative expression of miR-22. The experiment was repeated three times.

Table 2.

Primers sequences of quantitative reverse transcription-PCR (qRT-PCR)

Gene 　 Sequence
miR-22 Forward 5’-ACACTCCAGCTGGGAAGCTGCCAGTTGAAG-3’
Reverse 5’-GGTGTCGTGGAGTCGGCAA-3’
U6 Forward 5’-CTCGCTTCGGCAGCACATATACT-3’
　 Reverse 5’-ACGCTTCACGAATTTGCGTGTC-3’
Open in a new tab

Immunohistochemistry

Lung tissues were embedded in paraffin and sliced into 4 μm sections, which were baked and immersed into a newly-prepared xylene solution for 10 min twice. Then, dewaxing was performed with gradient alcohol for 5 min. After washing with water, slides were incubated for 10 min with 3% H2O2 at 37 °C. Next, sections were blocked for 30 min with normal goat serum, washed for 5 min × 3 times with PBS, and primary antibody solution (PCNA: 1:10000 dilution, ab29; Ki67: 1:100 dilution, ab16667, all purchased from Abcam, Cambridge, MA, USA) added for overnight reaction at 4 °C. Then, a secondary antibody was added for 30 min at 37 °C, and cells were washed with PBS three times within 30 min at 37 °C. Later, color development was performed with DAB for 20 min under a light microscope and terminated with PBS before routine dehydration with ethanol, hyalinization with xylene, and section sealing with neutral resin. Two independent investigators examined all tumor sections randomly. Five views were examined per section, and 100 cells were observed per view at 400 ×magnification. The number of positive cells was counted, and the proliferation index (PI) of PCNA and Ki67 was calculated, with the formula PI = number of positive cells/total cell number× 100% (28). The experiment was repeated three times.

Western blotting

Total protein in lung tissues was extracted, and its concentration was determined according to the instructions of the BCA Kit (Wuhan BOSTER Biological Technology Co., Ltd, China). Then, loading buffer was added into the extracted protein samples to boil for 10 min at 95 °C before loading samples 40 ug/hole. Next, 10% polyacrylamide gel was used to separate proteins by electrophoresis with the voltage of 80V for concentration gel and 120V for separation gel. The wet transfer was utilized with constant 100 mV for 90–120 min of PVDF membrane transferring. After blocking with 5% BSA at room temperature for 1 hr, primary antibodies PCNA (1 µg/ml, ab29), Ki-67(1 µg/ml, ab16667), Bax (1:1000 dilution, ab32503), Bcl-2 (1:1000 dilution, ab32124), Caspases-3 (1:500 dilution, ab2171), and β-actin(1:10000 dilution, ab8226) (all purchased from Abcam, Cambridge, MA, USA) were added for overnight incubation at 4 °C. Next, cells were washed with TBST for 5 min × 3 times before adding corresponding secondary antibodies for another 1 hr of incubation. Last, cells were washed again with TBST for 5 min × 3 times before developing with chemiluminescence reagent. β-actin was used as the loading control, and the experiment was repeated three times.

TUNEL staining

Lung tissue samples were prepared into frozen sections, which were dried at room temperature and blocked for 1 hr using 3%BSA Tris-Hcl (Roche). Then, sections were washed with PBS and 50 μl of TUNEL reaction mixture were added for 1 hr of incubation at 37 °C, 3% H2O2 to block endogenous peroxidase, as well as peroxidase-labeled fluorescence antibody for 30 min of incubation. Next, after washing three times with PBS, sections were mounted with glycerol and placed under an OLYMPUS fluorescence microscope for observation and picture taking. The number of TUNEL staining positive cells was counted and the rate of apoptotic cells was calculated with the formula: rate of apoptotic cells = number of apoptotic cells/ total cell number × 100%. The experiment was repeated three times.

Statistical method

The statistical data were analyzed using SPSS 22.0 and GraphPad Prism 6.0 software packages. Measurement data were presented by mean ± standard deviation (±s). One-way ANOVA was used for differences between multiple groups followed by Tukey’s HSD (honestly significant difference) test to compare the difference between two groups. The IC50 values were calculated using GraphPad Prism 6.0 with the nonlinear regression curve fit. Survival analysis was performed using the Kaplan-Meier curve. P<0.05 was considered statistically different.

Results

Both BPI-2009H and LY-231514 increased the inhibition rate of HCC827 cells, which was enhanced by anti-miR-22

As demonstrated in Figures 1A-B, miR-22 expression was significantly decreased in HCC827 cells after treatment of BPI-2009H or LY-231514 in a dose-dependent manner. Besides, the IC50 values of BPI-2009H and LY-231514 on HCC827 cells were 1.67±0.33 μmol/l and 0.74±0.09 μg/ml, respectively, which were decreased by the transfection of anti-miR-22 with IC50 values of 0.064±0.004 μmol/l and 0.014±0.002 μg/ml, respectively (Figures 1C-D).

Figure 1.

BPI-2009H and LY-231514 increased the inhibition rate of HCC827 cells, which was enhanced by anti-miR-22

Figure 1

Note: qRT-PCR was used to detect the expression of miR-22 in HCC827 cells treated with BPI-2009H (A) and LY-231514 (B), Same letters showed no significant difference, P>0.05; different letters showed the statistically significant difference, P<0.05; C-D: anti-miR-22 increased the inhibition rate of HCC827 treated with BPI-2009H (C) and LY-231514 (D)

Open in a new tab

General information of rats

One week after subcutaneous tumor inoculation, all rats had solid tumors (100% tumor formation rate), and the tumor volume showed no significant difference between groups (all P>0.05). From the beginning of the 2nd week, compared with the Control group, the tumor growth of rats in the other groups was inhibited to some extent. And the obvious differences of tumor volume and bodyweight loss were observed since the 4th week between groups (all P<0.05). Changes in the tumor volume and bodyweight loss are demonstrated in Figures 2A-C. Besides, significant difference in the prognosis of rats was found between the groups with the highest survival rate in anti-miR-22 + BPI-2009H + LY-231514 group (Figure 2D, P<0.001).

Figure 2.

General information of rats

Figure 2

Note: A-B, The tumor volume (mm3) and bodyweight loss (%) of rats in each group from one week after subcutaneous tumor inoculation; C: Image of representative tumors collected from rats at the end of the experiment; D: Survival curves of rats in each group

Open in a new tab

Expression of miR-22 in lung tumor tissues of rats in each group

According to the qRT-PCR results, anti-miR-22 + BPI-2009H + LY-231514 group showed the lowest expression of miR-22 in lung tumor tissues among those ten groups (all P<0.05). In addition, as compared with the Control group, BPI-2009H and LY-231514 groups had a remarkably lowered expression of miR-22. Moreover, the combination treatment of BPI-2009H and LY-231514 decreased the miR-22 expression when compared with the treatment of BPI-2009H or LY-231514 alone (both P<0.05, Figure 3).

Figure 3.

qRT-PCR was used to detect the expression of miR-22 in lung tumor tissues of rat

Figure 3

Note: Same letters showed no significant difference, P>0.05; different letters showed statistically significant difference, P<0.05

Open in a new tab

Expression of PCNA and Ki67 in lung tumor tissues of rats in each group

Immunohistochemical staining showed positive PCNA and Ki67 expression (brown-yellow particles) localized in the nuclei (Figure 4A). By comparison with the Control group, the proliferative indices (PIs) of PCNA and Ki67 in lung tumor tissues of other groups were significantly decreased (all P<0.05). Further, when compared with BPI-2009H + LY-231514, the PIs of PCNA and Ki67 were obviously lowered in the anti-miR-22+BPI-2009H + LY-231514 group (both P<0.05, Figures 4B-C). Besides, Western blotting was also performed to measure the protein expression of PCNA and Ki-67 in lung tumor tissues (Figure 5), which presented to be consistent with those of immunohistochemistry staining.

Figure 4.

The expression of PCNA and Ki67 in lung tumor tissues of rats in each group detected by immunohistochemistry staining

Figure 4.

Note: A, Representative sections stained for PCNA and Ki67 detected by immunohistochemistry staining; B–C, The statistical analysis of the proliferative indices (PIs) of PCNA (B) and Ki-67 (C) in lung tissues; same letters showed no significant difference, P>0.05; different letters showed statistically significant difference, P<0.05

Open in a new tab

Figure 5.

Protein expressions of PCNA and Ki-67 in lung tumor tissues of rats in each group by Western blotting

Figure 5

Note: Same letters showed no significant difference, P>0.05; different letters showed statistically significant difference, P<0.05

Open in a new tab

Cell apoptosis in lung tumor tissues of rats in each group

When compared with the Control group, the cell apoptosis rate in lung tumor tissues of rats in the rest of the groups was significantly increased with the up-regulation of Bax and Caspase-3 expression, as well as the down-regulation of Bcl-2 expression (all P<0.05). Moreover, rats in the anti-miR-22 + BPI-2009H + LY-231514 group had a notably higher apoptosis rate, obviously increased expression of Bax and caspases-3, as well as decreased expression of Bcl-2 (all P <0.05, Figure 6).

Figure 6.

Cell apoptosis in lung tumor tissues of rats in each group

Figure 6.

Note: A, Representative sections stained for apoptosis by TUNEL assay; B, The cell apoptosis rate in lung tumor tissues in each group; C-D, The protein expressions of Bax, Caspase-3, and Bcl-2 in lung tumor tissues of rats in each group detected by Western blotting. Same letters showed no significant difference, P>0.05; Different letters showed statistically significant difference, P<0.05. TUNEL, terminal deoxynucleotidyl transferase-mediated uridine 5’-triphosphate-biotin nick end labeling

Open in a new tab

Discussion

To date, the combination of chemotherapy and EGFR-TKIs has become a better choice in NSCLC, and we have carried out this study to determine the role of miR-22 in the efficacy of combined therapy in NSCLC rat model. Our results suggest that expression of miR-22 was decreased in HCC827 cells and NSCLC rats after treatment with BPI-2009H and/or LY-231514, and the tumor growth was significantly inhibited with prolonged survival rate and less bodyweight loss, especially evident in NSCLC rats with intratumoral injection of anti-miR-22, which could further improve the efficacy to a large extent. As is known to all, pemetrexed is a kind of multi-target anti-folic agent that can directly inhibit the activity of key enzymes during the metabolism of folic acid, thus inhibiting the growth of tumors (29). Meanwhile, miRNAs have been demonstrated to affect responses to pemetrexed through targeting key enzymes related to folate pathway proteins (30). For example, dihydrofolate reductase, as the target enzyme of inhibition by pemetrexed, was found to be modulated by miR-24 at the translational level (31). To our knowledge, miR-22 could directly target methylenetetrahydrofolate reductase (MTHFR), one of the critical enzymes in the metabolism of folic acid (32, 33). The gene polymorphism of MTHFR was found to be associated with the efficacy of pemetrexed therapy in patients with NSCLC (34), and 677C > T SNP in the MTHFR gene can lead to reduced expression of MTHFR as well as lowered levels of 5-methylTHF, resulting in the enhanced activity of TS and the decreased therapeutic effect of pemetrexed (35). These may provide an explanation that miR-22 may affect the curative efficacy of pemetrexed in patients with NSCLC by interfering with the metabolism of folic acid. Consistently, Franchina et al. also revealed that the expression of miR-22 was significantly reduced in NSCLC patients after treatment with pemetrexed (23). On the other hand, icotinib was also found capable of suppressing the Akt signaling pathway activation in human NSCLC cells (24), and over-expressed miR-22 can down-regulate phosphatase and tensin homolog and activate phosphoinositide 3-kinase (PI3K)/AKT pathway (25), showing that miR-22 may affect the icotinib efficacy in NSCLC through the Akt signaling pathway. Given the facts above, we hypothesized that inhibition of miR-22 might affect the therapeutic effect of icotinib plus pemetrexed through different mechanisms, thus enhancing their combined efficacy in the treatment of NSCLC.

Now that the main molecular mechanism of malignant tumors is the unrestricted proliferation and apoptosis reduction of tumor cells, inhibiting the malignant proliferation and inducing the apoptosis of tumor cells has become a hot topic for finding a new treatment for tumors (36, 37). Ki67 and PCNA, the most widely used proliferation labeling proteins, are expressed in the nucleus and closely related to cell cycles (38), which are more frequently down-regulated in good responders to treatment. As suggested by Horii et al. obvious decreases in Ki-67 and PCNA labeling indexes (LIs) were discovered in the surgical specimens of patients with esophageal squamous cell carcinoma who had neoadjuvant chemotherapy compared with those patients without preoperative treatment (39). Therefore, the expressions of Ki67 and PCNA were detected by immunohistochemistry, generally used clinically, in this study (40), and our result confirm that after the combined icotinib and pemetrexed treatment, the PIs of PCNA and Ki67 in the NSCLC rats injected with anti-miR-22 were appreciably lower than other resting groups, which is also consistent with our findings by using Western blotting. More importantly, some miRNAs can induce tumor cell proliferation, thereby reducing the sensitivity of drugs, such as miR-96, which can promote cell proliferation by targeting RECK and lower the chemotherapy sensitivity of esophageal cancer cells(41). Therefore, we hypothesized that inhibition of miR-22 might inhibit the proliferation of NSCLC cells and enhance the therapeutic effects of icotinib plus pemetrexed, thus affecting tumor growth. At the same time, mounting studies have proved the great significance of cell apoptosis dysfunction in the resistance to anticancer drugs, including icotinib and pemetrexed. Icotinib could lead to Tca8113 cell apoptosis possibly due to interfering with the reactive oxygen species-mediated MAPK pathway (42). Besides, by activating ataxia telangiectasia mutated (ATM)/p53-dependent and -independent signaling pathways, pemetrexed can promote both intrinsic as well as extrinsic apoptosis (43). Moreover, miRNAs may also be involved in the promotion of cell apoptosis combined with drugs. Tang et al. and his team reported that knockdown of the miR-183/96/182 cluster could improve the effect of Temozolomide in treating glioma by affecting the ROS-mediated apoptosis pathway (44). Similar to our findings, apoptosis-inhibited molecules (Bcl-2) were apparently lowered, but pro-apoptotic factors including Bax and Caspase-3 were greatly elevated in treated NSCLC rats with anti-miR-22, indicating that inhibition of miR-22 may promote apoptosis to increase the therapeutic outcomes and suppress the tumor growth.

Conclusion

Inhibition of miR-22 may inhibit cell proliferation and promote cell apoptosis to enhance the efficacy of combined icotinib & pemetrexed, thereby inhibiting the tumor growth of NSCLC. However, the mechanism of miR-22 in modulating the gene network or downstream pathways to affect the efficacy of combined therapy needs to be further explored in future studies.

Acknowledgment

We thank the reviewers for their helpful suggestions and comments.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Financial Source

None.

References

  • 1.Zhou C, Yao LD. Strategies to Improve Outcomes of Patients with EGRF-Mutant Non-Small Cell Lung Cancer: Review of the Literature. J Thorac Oncol. 2016;11:174–186. doi: 10.1016/j.jtho.2015.10.002. [DOI] [PubMed] [Google Scholar]
  • 2.Chen KY, Chen JH, Shih JY, Yang CH, Yu CJ, Yang PC. Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors. J Thorac Oncol. 2010;5:82–89. doi: 10.1097/JTO.0b013e3181c09b28. [DOI] [PubMed] [Google Scholar]
  • 3.Ho C, Ramsden K, Zhai Y, Murray N, Sun S, Melosky B, et al. Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based review. J Thorac Oncol. 2014;9:1180–1186. doi: 10.1097/JTO.0000000000000225. [DOI] [PubMed] [Google Scholar]
  • 4.Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–128. doi: 10.1016/S1470-2045(09)70364-X. [DOI] [PubMed] [Google Scholar]
  • 5.Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–742. doi: 10.1016/S1470-2045(11)70184-X. [DOI] [PubMed] [Google Scholar]
  • 6.Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4:36–54. doi: 10.3978/j.issn.2218-6751.2014.05.01. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Pirazzoli V, Ayeni D, Meador CB, Sanganahalli BG, Hyder F, de Stanchina E, et al. Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naive EGFR L858R-Induced Lung Adenocarcinoma. Clin Cancer Res. 2016;22:426–435. doi: 10.1158/1078-0432.CCR-15-0620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Xiao BK, Yang JY, Dong JX, Ji ZS, Si HY, Wang WL, et al. Meta-analysis of seven randomized control trials to assess the efficacy and toxicity of combining EGFR-TKI with chemotherapy for patients with advanced NSCLC who failed first-line treatment. Asian Pac J Cancer Prev. 2015;16:2915–2921. doi: 10.7314/apjcp.2015.16.7.2915. [DOI] [PubMed] [Google Scholar]
  • 9.Stefanou D, Stamatopoulou S, Sakellaropoulou A, Akakios G, Gkiaouraki M, Gkeka D, et al. Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases. Oncol Lett. 2016;12:4635–4642. doi: 10.3892/ol.2016.5268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Perez-Moreno MA, Cotrina-Luque J, Galvan-Banqueri M, Flores-Moreno S, Bautista-Paloma FJ, Calleja-Hernandez MA. Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System. Farm Hosp. 2016;40(n06):477–485. doi: 10.7399/fh.2016.40.6.10424. [DOI] [PubMed] [Google Scholar]
  • 11.Park S, Kim HJ, Choi CM, Lee DH, Kim SW, Lee JS, et al. Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed. BMC Cancer. 2016;16:417. doi: 10.1186/s12885-016-2457-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Paz-Ares LG, Zimmermann A, Ciuleanu T, Bunn PA, Antonio BS, Denne J, et al. Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer. Lung Cancer. 2017;104:45–51. doi: 10.1016/j.lungcan.2016.12.007. [DOI] [PubMed] [Google Scholar]
  • 13.Yao S, Qian K, Wang R, Li Y, Zhang Y. [Comparison of the efficacy and safety of icotinib with standard second-line chemotherapy in previously treated advanced non-small cell lung cancer] Zhongguo Fei Ai Za Zhi. 2015;18:369–373. doi: 10.3779/j.issn.1009-3419.2015.06.07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Zheng Y, Fang W, Deng J, Zhao P, Xu N, Zhou J. Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status. J Thorac Dis. 2014;6:958–964. doi: 10.3978/j.issn.2072-1439.2014.07.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Jaiswal R, Raymond Grau GE, Bebawy M. Cellular communication via microparticles: role in transfer of multidrug resistance in cancer. Future Oncol. 2014;10:655–669. doi: 10.2217/fon.13.230. [DOI] [PubMed] [Google Scholar]
  • 16.Karimi Kurdistani Z, Saberi S, Tsai KW, Mohammadi M. MicroRNA-21: Mechanisms of Oncogenesis and its Application in Diagnosis and Prognosis of Gastric Cancer. Arch Iran Med. 2015;18:524–536. [PubMed] [Google Scholar]
  • 17.Song N, Ma X, Li H, Zhang Y, Wang X, Zhou P, et al. microRNA-107 functions as a candidate tumor suppressor gene in renal clear cell carcinoma involving multiple genes. Urol Oncol. 2015;33:205 e1–11. doi: 10.1016/j.urolonc.2015.02.003. [DOI] [PubMed] [Google Scholar]
  • 18.Ling B, Wang GX, Long G, Qiu JH, Hu ZL. Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3. J Cancer Res Clin Oncol. 2012;138:1355–1361. doi: 10.1007/s00432-012-1194-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Zhang K, Li XY, Wang ZM, Han ZF, Zhao YH. MiR-22 inhibits lung cancer cell EMT and invasion through targeting Snail. Eur Rev Med Pharmacol Sci. 2017;21:3598–3604. [PubMed] [Google Scholar]
  • 20.Wang J, Li Y, Ding M, Zhang H, Xu X, Tang J. Molecular mechanisms and clinical applications of miR-22 in regulating malignant progression in human cancer (Review) Int J Oncol. 2017;50:345–355. doi: 10.3892/ijo.2016.3811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Li J, Zhang Y, Zhao J, Kong F, Chen Y. Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. Mol Cell Biochem. 2011;357:31–38. doi: 10.1007/s11010-011-0872-8. [DOI] [PubMed] [Google Scholar]
  • 22.Bo W, Li D, Filkowski J, Rodriguezjuarez R, Storozynsky Q, Malach M, et al. A dual role of miR-22 modulated by RelA/p65 in resensitizing fulvestrant-resistant breast cancer cells to fulvestrant by targeting FOXP1 and HDAC4 and constitutive acetylation of p53 at Lys382. Oncogenesis. 2018;7:1–14. doi: 10.1038/s41389-018-0063-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Franchina T, Amodeo V, Bronte G, Savio G, Ricciardi GR, Picciotto M, et al. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J Cell Physiol. 2014;229:97–99. doi: 10.1002/jcp.24422. [DOI] [PubMed] [Google Scholar]
  • 24.Mu X, Ye Z, Qu X, Hou K, Jian K, Liu Y. The effects of Icotinib on the activation of Akt and the expressions of apoptosis-related proteins in human NSCLC cells. Modern Oncology. 2013;21:686–689. [Google Scholar]
  • 25.Palacios F, Abreu C, Prieto D, Morande P, Ruiz S, Fernandez-Calero T, et al. Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation. Leukemia. 2015;29:115–125. doi: 10.1038/leu.2014.158. [DOI] [PubMed] [Google Scholar]
  • 26.Orlans FB. Ethical decision making about animal experiments. Ethics Behav. 1997;7:163–1671. doi: 10.1207/s15327019eb0702_7. [DOI] [PubMed] [Google Scholar]
  • 27.Pal HC, Sharma S, Strickland LR, Agarwal J, Athar M, Elmets CA, et al. Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways. PLoS One. 2013;8:e77270. doi: 10.1371/journal.pone.0077270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Liang X, Lan C, Zhou J, Fu W, Long X, An Y, et al. Development of a new analog of SGK1 inhibitor and its evaluation as a therapeutic molecule of colorectal cancer. J Cancer. 2017;8:2256–2262. doi: 10.7150/jca.19566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Liew SC. Folic acid and diseases - supplement it or not? Rev Assoc Med Bras (1992) 2016;62:90–100. doi: 10.1590/1806-9282.62.01.90. [DOI] [PubMed] [Google Scholar]
  • 30.Marsit CJ, Eddy K, Kelsey KT. MicroRNA responses to cellular stress. Cancer Res. 2006;66:10843–8. doi: 10.1158/0008-5472.CAN-06-1894. [DOI] [PubMed] [Google Scholar]
  • 31.Shookhoff JM, Gallicano GI. A new perspective on neural tube defects: folic acid and microRNA misexpression. Genesis. 2010;48:282–294. doi: 10.1002/dvg.20623. [DOI] [PubMed] [Google Scholar]
  • 32.Koturbash I, Melnyk S, James SJ, Beland FA, Pogribny IP. Role of epigenetic and miR-22 and miR-29b alterations in the downregulation of Mat1a and Mthfr genes in early preneoplastic livers in rats induced by 2-acetylaminofluorene. Mol Carcinog. 2013;52:318–327. doi: 10.1002/mc.21861. [DOI] [PubMed] [Google Scholar]
  • 33.Stone N, Pangilinan F, Molloy AM, Shane B, Scott JM, Ueland PM, et al. Bioinformatic and genetic association analysis of microRNA target sites in one-carbon metabolism genes. PLoS One. 2011;6:e21851. doi: 10.1371/journal.pone.0021851. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, et al. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer. 2012;78:92–99. doi: 10.1016/j.lungcan.2012.07.009. [DOI] [PubMed] [Google Scholar]
  • 35.Kucharczyk T, Krawczyk P, Powrozek T, Kowalski DM, Ramlau R, Kalinka-Warzocha E, et al. The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients. Pathol Oncol Res. 2016;22:49–56. doi: 10.1007/s12253-015-9966-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Ren KW, Li YH, Wu G, Ren JZ, Lu HB, Li ZM, et al. Quercetin nanoparticles display antitumor activity via proliferation inhibition and apoptosis induction in liver cancer cells. Int J Oncol. 2017;50:1299–1311. doi: 10.3892/ijo.2017.3886. [DOI] [PubMed] [Google Scholar]
  • 37.Li R, Yang HQ, Xi HL, Feng S, Qin RH. Inhibition of CDH17 gene expression via RNA interference reduces proliferation and apoptosis of human MKN28 gastric cancer cells. Int J Oncol. 2017;50:15–22. doi: 10.3892/ijo.2016.3783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Sanchez DI, Gonzalez-Fernandez B, San-Miguel B, de Urbina JO, Crespo I, Gonzalez-Gallego J, et al. Melatonin prevents deregulation of the sphingosine kinase/sphingosine 1-phosphate signaling pathway in a mouse model of diethylnitrosamine-induced hepatocellular carcinoma. J Pineal Res. 2017;62:e12369. doi: 10.1111/jpi.12369. [DOI] [PubMed] [Google Scholar]
  • 39.Horii N, Nishimura Y, Okuno Y, Kanamori S, Hiraoka M, Shimada Y, et al. Impact of neoadjuvant chemotherapy on Ki-67 and PCNA labeling indices for esophageal squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2001;49:527–532. doi: 10.1016/s0360-3016(00)01468-1. [DOI] [PubMed] [Google Scholar]
  • 40.Jurikova M, Danihel L, Polak S, Varga I. Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer. Acta Histochem. 2016;118:544–552. doi: 10.1016/j.acthis.2016.05.002. [DOI] [PubMed] [Google Scholar]
  • 41.Xia H, Chen S, Chen K, Huang H, Ma H. MiR-96 promotes proliferation and chemo- or radioresistance by down-regulating RECK in esophageal cancer. Biomed Pharmacother. 2014;68:951–958. doi: 10.1016/j.biopha.2014.10.023. [DOI] [PubMed] [Google Scholar]
  • 42.Yang C, Yan J, Yuan G, Zhang Y, Lu D, Ren M, et al. Induction of Tca8113 tumor cell apoptosis by icotinib is associated with reactive oxygen species mediated p38-MAPK activation. Pharmazie. 2014;69:629–632. [PubMed] [Google Scholar]
  • 43.Yang TY, Chang GC, Chen KC, Hung HW, Hsu KH, Wu CH, et al. Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways. Mol Carcinog. 2013;52:183–194. doi: 10.1002/mc.21842. [DOI] [PubMed] [Google Scholar]
  • 44.Tang H, Bian Y, Tu C, Wang Z, Yu Z, Liu Q, et al. The miR-183/96/182 cluster regulates oxidative apoptosis and sensitizes cells to chemotherapy in gliomas. Curr Cancer Drug Targets. 2013;13:221–231. doi: 10.2174/1568009611313020010. [DOI] [PubMed] [Google Scholar]

Articles from Iranian Journal of Basic Medical Sciences are provided here courtesy of Mashhad University of Medical Sciences

RESOURCES